Supplementary Materials

Supplementary Material for:

MM-151 overcomes acquired resistance to cetuximab and panitumumab in colorectal cancers harboring EGFR extracellular domain mutations

Sabrina Arena,* Giulia Siravegna, Benedetta Mussolin, Jeffrey D. Kearns, Beni B. Wolf, Sandra Misale, Luca Lazzari, Andrea Bertotti, Livio Trusolino, Alex A. Adjei, Clara Montagut, Federica Di Nicolantonio, Rachel Nering, Alberto Bardelli*

*Corresponding author. E-mail: sabrina.arena{at}ircc.it (S.A.); alberto.bardelli{at}unito.it (A.B.)

Published 3 February 2016, Sci. Transl. Med. 8, 324ra14 (2016)
DOI: 10.1126/scitranslmed.aad5640

This PDF file includes:

  • Fig. S1. Nucleotide sequence of the EGFR p.G465E mutation in HCA-46 R5.
  • Fig. S2. EGF tracer dose response assay in HEK-293 cells expressing EGFR ECD mutants.
  • Fig. S3. Effects of EGFR blockade on LIM1215 overexpressing EGFR ectodomain mutants.
  • Fig. S4. Effects of EGFR blockade on proliferation in LIM1215 cells.
  • Fig. S5. Effects of EGFR blockade on proliferation in CCK-81 cells.
  • Fig. S6. Effects of EGFR blockade on proliferation in HCA-46 cells.
  • Table S1. Mean, SD, and P values for the NanoLuc drug displacement assay.
  • Table S2. Mean, SD, and P values for the LIM1215 cell viability assay.
  • Table S3. Effects of anti-EGFR blockade in cetuximab-resistant cells.
  • Table S4. ddPCR mutation assays for KRAS, BRAF, and NRAS.
  • Table S5. ddPCR custom-designed assays for EGFR ECD mutations

[Download PDF]